VERTEX PHARMACEUTICALS INC / MA
Company Stats
- Market Cap
- $132.5B
- as of Sep 30, 2026
- Shares Outstanding
- 253.5M
- Free Float
- 99.8%
Income Statement
- Revenue
- $12.0B
- Operating Income
- $4.2B
- Net Income
- $4.0B
- EBITDA
- $4.4B
- Non-cash Impairment
- $379.0M
- Revenue Growth, 3Y
- 10.4%
- FCF Margin, 3Y Avg
- 17.8%
- FCF Margin, Worst Year
- -7.2%
Cash Flow
- Free Cash Flow
- $3.2B
- FCF Yield
- 2.4%
- Owner FCF Yield
- 1.9%
Balance Sheet
- Cash & Equivalents
- $5.1B
Returns & Capital
- Share Repurchases
- $2.0B
- Buyback Yield, 3Y Avg
- 0.9%
- SBC, 3Y Avg
- $655.2M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $12.0B | $3.2B | 26.6% |
| FY2024 | $11.0B | -$790.3M | -7.2% |
| FY2023 | $9.9B | $3.3B | 33.8% |
| FY2022 | $8.9B | $3.9B | 44.0% |
| FY2021 | $7.6B | $2.4B | 31.8% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 23, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back